ArticleResearch (Washington, D.C.)2025
Neonatal-Inspired Reprogramming of Microglial Pan-Programmed Cell Death Enhances Regeneration in Adult Spinal Cord Injury.
Article in Research (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Microglia and neuroinflammation: An in-depth analysis from functional diversity to disease mechanisms.Clinical and translational medicine · 2026Review
- [Mechanisms of Piezo1-mediated microglial ferroptosis in inhibiting spinal cord injury repair].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026Article
- Persistent histone H3K27 acetylation contributes to excessive scar formation after spinal cord injury through the regulation of microglial cholesterol accumulation.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Targeting microglial MyD88 reprograms injury-activated microglia and promotes spinal cord repair via TGF-β signaling and biomimetic nanodelivery.Theranostics · 2026Article
- Mechanical Remodeling and Mechanosensing after Spinal Cord Injury: From Molecular to Translational Approaches.Research (Washington, D.C.) · 2026Review
- The role of post-translational modifications in osteonecrosis of the femoral head.Frontiers in cell and developmental biology · 2026Review
- Copper-Iron Cell Death Axis: Mechanistic Crosstalk, Disease Implications and an Integrated Metallo-Redox-Metabolic Framework.International journal of biological sciences · 2026Review
- Retinoic Acid-Loaded Cartilage Organoids Attenuate Chondrocyte Senescence in Osteoarthritis.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In adult mammals, programmed cell death (PCD) facilitates tissue remodeling and regeneration in spinal cord injury (SCI), but excessive activation impedes SCI repair. However, no comprehensive pan-PCD atlas exists that encompasses diverse cell death patterns to fully elucidate PCD in adult SCI and develop strategies for modulating the excessive PCD response. Here, we identified neonatal mice with balanced PCD post-SCI as an ideal model for adult SCI. Accordingly, we developed "Thanatoset", an SCI-specific gene panel to map tissue and cellular pan-PCD dynamics across neonatal and adult mice. Microglia were identified as pivotal mediators of pan-PCD, showing greater vulnerability in adults than in neonates. According to computational drug screening, withaferin A can revert microglial pan-PCD in adults to a neonatal-like regenerative state. Histological, functional, and molecular analyses corroborated that withaferin A enhances SCI recovery in adults by modulating microglial pan-PCD. These findings highlight the therapeutic potential of the pan-PCD framework for developing strategies to restore regeneration and improve SCI outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.